Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti‐MDA5 antibody‐positive dermatomyositis related interstitial lung disease
The Clinical Respiratory Journal · 2023
DOI: 10.1111/crj.13616 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2023. Verfasst von Yan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Dermatomyositis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanjing Municipal Health and Family Planning Commission, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Introduction
The prognosis of anti‐MDA5 antibody‐positive dermatomyositis/clinically amyopathic dermatomyositis‐associated interstitial lung disease (MDA5‐DM/CADM‐ILD) is poor. This study was to evaluate the effect of serum soluble CD206 (sCD206), a biomarker of macrophage activation, on predicting the interstitial lung disease (ILD) deterioration and prognosis for MDA5‐DM/CADM‐ILD.
Methods
Forty‐one patients diagnosed with MDA5‐DM/CADM‐ILD were retrospectively included. The clinical data were analyzed. Serum sCD206 levels were measured in 41 patients and 30 healthy controls. The relation between sCD206 levels and ILD deterioration was assessed. Receiver operating characteristic (ROC) curve was generated to determine the optimal cut‐off value of sCD206 for predicting outcome. The association between sCD206 and survival was examined.
Results
The median serum sCD206 level in patients was significantly higher than healthy controls (464.1 ng/mL vs. 349.1 ng/mL, P = 0.002). In DM/CADM patients, the sCD206 level was significantly higher in patients with acute/subacute interstitial lung disease (AILD/SILD) than those with chronic interstitial lung disease (CILD) (539.2 ng/mL vs. 309.4 ng/mL, P = 0.005). The AUC of sCD206 was 0.885 for predicting mortality (95% CI 0.779–0.990). Patients were divided into two groups: sCD206 high level group (≥400 ng/mL) and sCD206 low level group (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
- Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
ORCID-Profile: Hourong Cai
Förderung
- Nanjing Municipal Health and Family Planning Commission
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Li, Y., Liu, X., Tian, M., Zou, R., Gao, Y., Huang, M., Zhou, K., Cao, M., & Cai, H. (2023). Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti‐MDA5 antibody‐positive dermatomyositis related interstitial lung disease. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13616
Vancouver
Li Y, Liu X, Tian M, Zou R, Gao Y, Huang M, et al. Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti‐MDA5 antibody‐positive dermatomyositis related interstitial lung disease. The Clinical Respiratory Journal. 2023. doi:10.1111/crj.13616
BibTeX
@article{Li2023,
author = {Li, Yan and Liu, Xiaoqin and Tian, Mi and Zou, Ruyi and Gao, Yujuan and Huang, Mei and Zhou, Kefeng and Cao, Min and Cai, Hourong},
title = {Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti‐MDA5 antibody‐positive dermatomyositis related interstitial lung disease},
journal = {The Clinical Respiratory Journal},
year = {2023},
doi = {10.1111/crj.13616}
}
EUVIMED